Pfizer Inc. y BioNTech They said this Saturday that a booster dose of the updated versions of your anticovid vaccinespecifically modified to combat Omicron variantgenerated a greater immune response against that strain.
It is expected that the advisers of the United States Food and Drug Administration (FDA) meet on Tuesday to discuss whether to update the vaccines against covid-19 for the boreal fall.
According to experts, the updated injections are likely to be redesigned to combat the Omicron variant.
Pfizer and BioNTech explained that the 30- and 60-microgram doses of a vaccine targeting only the BA.1 Omicron subvariant that circulated last winter caused a 13.5- and 19.6-fold increase in neutralizing geometric titers against that subvariate.
A version of the vaccine that contained both the redesigned and original vaccines caused a 9.1- and 10.9-fold increase, they noted.
The results came from a trial of 1,234 people aged 56 and older.
The vaccines were well tolerated by the participants, according to the companies.
The companies noted that early laboratory studies suggest that both Omicron-modified candidates neutralize the BA.4 and BA.5 subvariants that have been circulating more recently, although to a lesser extent than for BA.1, with approximately 3-fold lower titers.
The companies said they continue to collect data on the performance of the boosters against the strains that have circulated most recently.
Moderna Inc. has also manufactured a redesigned vaccine targeting the BA.1 subvariant of Omicron.
The company said its updated vaccine worked well against the latest Omicron subvariants, and it was moving forward with plans to apply for regulatory approval.
jrr
–
